MAAT INDEX

CLAIM #18629 · CVS Health Corp (CVS) · 2025Q4 earnings call · Feb 10, 2026 · due Dec 31, 2026

We have clear line of sight to improved performance in Health Care Delivery, in Oak Street Health in 2026, and we'll continue to make progress in future years.

Sreekanth Chaguturu · Executive

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Health Care Delivery segment operating income (and/or Oak Street Health operating results), fiscal year 2026 vs. fiscal year 2025

It came true if: Health Care Delivery segment operating income (loss) in FY2026 improves versus FY2025 reported figure (less negative or higher profit)

Where: Company segment financial disclosures (10-K / Q4 2026 earnings release, Health Care Delivery segment results)

In context

e business forward. J. Joyner: Sree? Sreekanth Chaguturu: Thanks, David. Thanks, Steve. So as David mentioned, we are pleased to see the value of in-home provider visits are maintained, and that's a recognition of the importance of Signify's business model. And we'll continue to provide this value to payer, partners and members. However, as you've heard from David and Steve, the proposed rates fail to match utilization to cost trends, particularly as member needs become more complex. We firmly believe in the importance of value-based care. Oak Street Health is a best-in-class model. It delivers better outcomes and better experiences at lower cost for the patients we serve. We will continue to assess the rate notice to understand the full impact and continue to share our insights with CMS. We have clear line of sight to improved performance in Health Care Delivery, in Oak Street Health in 2026, and we'll continue to make progress in future years. Operator: Our next question comes from Lisa Gill with JPMorgan. Lisa Gill: David, I just want to follow up on a couple of your comments you made as it relates to the PBM side of the business. First, when you talked about regulatory, you said we're all for any type of regulation that doesn't impact the ability to create competition in the supply chain. So I have really a 3-part question here. The first is, do you feel that currently what the FTC is proposing would, in some way, hinder your ability to negotiate in the supply chain? And is that the reason that we haven't seen some type of settlement yet for CVS Health? And then secondly, when I think about the PBM legislation, again, you talked about how that's manageable. We've seen you really start to shift your business towards transparen

Verify independently

SEC filings for CVS · Claim quote is verbatim from the 2025Q4 earnings call.